About the study
We’re investigating a potential new treatment for Cryopyrin Associated Periodic Syndrome (CAPS), a condition in which the body fails to adequately regulate inflammation.
CAPS is an inherited disease caused by a gene mutation that results in a defect in cryopyrin, a protein that plays in an important role in controlling inflammation. CAPS occurs in all age groups in both men and women and causes episodes of fever, a hive-like rash; joint pain and swelling; red eyes and headaches.
The purpose of this research is to determine if the study drug acts to reduce the harmful effects of inflammation. Current available therapies for CAPS are all injectable whereas we are investigating a small molecule medication which can be given by mouth in the form of capsules.
Participants will be reimbursed $3,500 for their participation in this study and this clinical trial has been approved by an independent ethics committee.